Case number 2016-1619
Supernus Pharmaceuticals, Inc v. Actavis Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | SUPERNUS PHARMACEUTICALS, INC v. ACTAVIS INC. [RULE 36 JUDGMENT] [nonprecedential] (0) |
| Jan 18, 2017 | 77 | Mandate issued to the United States District Court for the District of New Jersey. Costs taxed in the amount of $750.24. Service as of this date by Clerk of Court. [399763] [MJL] [Entered: 01/18/2017 09:03 AM] (1) |
| Dec 22, 2016 | 76 | Bill of Costs for Appellee Supernus Pharmaceuticals, Inc.. Service: 12/22/2016 by email. Objection to Bill of Costs due on 01/09/2017. [393532] [Nicholas Giove] [Entered: 12/22/2016 11:52 AM] (0) |
| Dec 12, 2016 | 75 | OPINION and JUDGMENT filed. The judgment or decision is: Affirmed. (FCR 36). (For the Court: Dyk,Circuit Judge; Clevenger,Circuit Judge and Stoll,Circuit Judge). [389944] [IW] [Entered: 12/12/2016 09:12 AM] (6) |
| Dec 8, 2016 | 74 | Submitted after ORAL ARGUMENT by Charles A. Weiss for Watson Laboratories, Inc., Watson Laboratories, Inc. - Florida, Actavis Pharma, Inc., Actavis Inc. and Anda, Inc. and Nicholas F. Giove for Supernus Pharmaceuticals, Inc.. Panel: Judge: Dyk , Judge: Clevenger , Judge: Stoll. [389374] [JAB] [Entered: 12/08/2016 10:43 AM] (0) |
| Nov 22, 2016 | 73 | Response to oral argument order from the Appellee Supernus Pharmaceuticals, Inc.. designating Nicholas F. Giove as arguing attorney. Designated time for argument: 15 minutes. Designated time for rebuttal: 0 minutes. Service of other counsel by Notice of Docket Activity from this entry. [385450] [Jonathan Herstoff] [Entered: 11/22/2016 12:42 PM] (0) |
| Nov 14, 2016 | 72 | Response to oral argument order from the Appellee Supernus Pharmaceuticals, Inc.. designating Edgar H. Haug as arguing attorney. Designated time for argument: 15 minutes. Designated time for rebuttal: 0 minutes. Service of other counsel by Notice of Docket Activity from this entry. [382444] [Nicholas Giove] [Entered: 11/14/2016 11:44 AM] (0) |
| Nov 14, 2016 | 71 | Response to oral argument order from the Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida. designating Charles A. Weiss as arguing attorney. Designated time for argument: 12 minutes. Designated time for rebuttal: 3 minutes. Service of other counsel by Notice of Docket Activity from this entry. [382403] [Charles Weiss] [Entered: 11/14/2016 10:57 AM] (0) |
| Nov 14, 2016 | 70 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:calendar response Docket No. [69] Counsel for appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida submitted a Response to Oral Argument Order indicating 15 minutes for argument time and 3 minutes for rebuttal. The Oral Argument Order states that unless otherwise direcetd by the court, total argument time is 15 minutes per side. Please re-file your response to oral argument order correcting the error by midnight on the date of this notice. [382392] [JAB] [Entered: 11/14/2016 10:48 AM] (0) |
| Nov 14, 2016 | 69 | Response to oral argument order from the Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida. designating Charles A. Weiss as arguing attorney. Designated time for argument: 15 minutes. Designated time for rebuttal: 3 minutes. Service of other counsel by Notice of Docket Activity from this entry. [382381] [Charles Weiss] [Entered: 11/14/2016 10:39 AM] (0) |
| Nov 2, 2016 | 68 | Amended Certificate of Interest for the Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida. Service: 11/02/2016 by email. [379717] [Charles Weiss] [Entered: 11/02/2016 02:22 PM] (3) |
| Oct 21, 2016 | 67 | NOTICE OF CALENDARING. Panel: 1612K. Case scheduled Dec 08, 2016 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, N.W. Washington, DC 20439), Courtroom 201. Response to oral argument order due: 11/15/2016. Counsel should check-in 30 minutes prior to the opening of the session. Please review the Oral Argument Order. [376570] THIS NOTICE APPLIES TO CASE(S): [16-1619, 16-1627, 16-1378, 16-1800] [JAB] [Entered: 10/21/2016 01:14 PM] (0) |
| Aug 2, 2016 | 66 | 6 paper copies of the Confidential Joint Appendix (Vol. I-II) [60] received from Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida. [355544] [KW] [Entered: 08/02/2016 03:53 PM] (0) |
| Aug 1, 2016 | 65 | Clerk's Note to the File: 6 CD-ROM copies of the Non-Confidential Corresponding Briefs and Joint Appendix received from Actavis Inc., et al. [355297] [KW] [Entered: 08/02/2016 09:42 AM] (0) |
| Aug 1, 2016 | 64 | Clerk's Note to the File: 6 CD-ROM copies of the Confidential Corresponding Briefs and Joint Appendix received from Actavis Inc., et al. [355296] [KW] [Entered: 08/02/2016 09:41 AM] (0) |
| Aug 1, 2016 | 63 | Notice from Appellee Supernus Pharmaceuticals, Inc. regarding conflicts with oral argument (October 3-7, 2016). Service: 08/01/2016 by email. [354915] [Nicholas Giove] [Entered: 08/01/2016 11:42 AM] (2) |
| Jul 29, 2016 | 62 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a)and Fed. Cir. R. 47.3 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. If the parties have already fulfilled these requirements, no further action is required in response to this notice. [354738] [AT] [Entered: 07/29/2016 04:19 PM] (0) |
| Jul 29, 2016 | 61 | Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court argument weeks [OCT, NOV, DEC], or thereafter if conflicts are known. When filing the notice of conflicts, counsel should docket the ECF event Notice Regarding Conflicts with Argument Dates, which is found in the Calendar event category. [354736] [AT] [Entered: 07/29/2016 04:18 PM] (0) |
| Jul 29, 2016 | 60 | CONFIDENTIAL JOINT APPENDIX FILED for Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida [57]. Number of Pages: 923. Service: 07/29/2016 by US mail. Pursuant to Fed. Cir. R. 28(d)(2)(A) six paper copies should be filed of the confidential version only. [354728] [AT] [Entered: 07/29/2016 04:12 PM] (0) |
| Jul 29, 2016 | 59 | APPENDIX FILED for Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida [56]. Number of Pages: 923. Service: 07/29/2016 by email. Pursuant to Fed. Cir. R. 30(a)(5), filer is directed to file six copies of the confidential version of the appendix in paper format. The paper copies should be received by the court on or before 08/03/2016. [354722] [AT] [Entered: 07/29/2016 04:09 PM] (923) |
| Jul 29, 2016 | 58 | Notice of intent to file corresponding briefs on CD-ROM for Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida. Service: 07/29/2016 by email. [354689] [Charles Weiss] [Entered: 07/29/2016 03:19 PM] (3) |
| Jul 29, 2016 | 57 | TENDERED from Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida. Title: CONFIDENTIAL JOINT APPENDIX Service: 07/29/2016 by email. [354608] [Charles Weiss] [Entered: 07/29/2016 01:25 PM] (0) |
| Jul 29, 2016 | 56 | TENDERED from Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida. Title: JOINT APPENDIX. Service: 07/29/2016 by email. [354603] [Charles Weiss] [Entered: 07/29/2016 01:18 PM] (923) |
| Jul 29, 2016 | 55 | Statement of Compliance with Fed. Cir. R. 33 for Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida. Service: 07/29/2016 by email. [354598] [Charles Weiss] [Entered: 07/29/2016 01:08 PM] (2) |
| Jul 26, 2016 | 54 | 6 paper copies of the Reply Brief [53] received from Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida. [354490] [KW] [Entered: 07/29/2016 09:15 AM] (0) |
| Jul 22, 2016 | 53 | REPLY BRIEF FILED for Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida [52]. Number of Pages: 28. Service: 07/22/2016 by email. Pursuant to Fed. Cir. R. 31(b), filer is directed to file six copies of the brief in paper format. The paper copies of the brief should be received by the court on or before 08/01/2016. Appendix is due 08/01/2016. [353382] [AT] [Entered: 07/25/2016 03:09 PM] (38) |
| Jul 22, 2016 | 52 | TENDERED from Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida. Title: REPLY BRIEF. Service: 07/22/2016 by email. [353085] [Charles Weiss] [Entered: 07/22/2016 04:21 PM] (38) |
| Jul 15, 2016 | 51 | 6 paper copies of the Confidential Response Brief [47] received from Appellee Supernus Pharmaceuticals, Inc. [351294] [KW] [Entered: 07/15/2016 03:29 PM] (0) |
| Jul 13, 2016 | 50 | NOTICE OF REJECTION: The paper copies of the Confidential Brief for Plaintiff-Appellee Supernus Pharmaceuticals, Inc. [49] are not in compliance with the rules of this court and are therefore rejected for filing. Corrected paper copies should be received by the court on or before 07/27/2016. Service as of this date by Clerk of Court. [350344] [MJL] [Entered: 07/13/2016 08:15 AM] (1) |
| Jul 12, 2016 | 49 | 6 paper copies of the Confidential Response Brief [47] received from Appellee Supernus Pharmaceuticals, Inc. [350285]. These paper copies have been rejected. See Doc. No. [50]. [KW] [Entered: 07/12/2016 04:05 PM] (0) |
| Jul 8, 2016 | 48 | BRIEF FILED for Appellee Supernus Pharmaceuticals, Inc. [46]. Number of Pages: 84. Service: 07/08/2016 by email. Pursuant to Fed. Cir. R. 31(b), filer is directed to file six copies of the confidential version of the brief in paper format. The paper copies should be received by the court on or before 07/18/2016. [349703] [MJL] [Entered: 07/11/2016 11:23 AM] (98) |
| Jul 8, 2016 | 47 | CONFIDENTIAL BRIEF FILED for Appellee Supernus Pharmaceuticals, Inc. [45]. Number of Pages: 84. Service: 07/08/2016 by email. Pursuant to Fed. Cir. R. 28(d)(2)(A) six paper copies should be filed of the confidential version only. [349701] [MJL] [Entered: 07/11/2016 11:20 AM] (0) |
| Jul 8, 2016 | 46 | TENDERED from Appellee Supernus Pharmaceuticals, Inc.. Title: RESPONSE BRIEF. Service: 07/08/2016 by email. [349583] [Nicholas Giove] [Entered: 07/08/2016 06:30 PM] (98) |
| Jul 8, 2016 | 45 | TENDERED from Appellee Supernus Pharmaceuticals, Inc.. Title: CONFIDENTIAL RESPONSE BRIEF Service: 07/08/2016 by email. [349582] [Nicholas Giove] [Entered: 07/08/2016 06:27 PM] (0) |
| Jul 7, 2016 | 44 | **TEXT ONLY** ORDER granting motion to withdraw attorney Rachael McClure [43] filed by Appellee Supernus Pharmaceuticals, Inc. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [349119] [SJ] [Entered: 07/07/2016 02:26 PM] (0) |
| Jul 7, 2016 | 43 | MOTION of Appellee Supernus Pharmaceuticals, Inc. to withdraw counsel Rachael Penman McClure. Response/Opposition is due 07/21/2016 [Consent: unopposed]. Service: 07/07/2016 by email. [349102] [Nicholas Giove] [Entered: 07/07/2016 01:48 PM] (4) |
| Jul 7, 2016 | 42 | Entry of appearance for Damon M. Lewis as of counsel for Appellee Supernus Pharmaceuticals, Inc.. Service: 07/07/2016 by email. [349098] [Nicholas Giove] [Entered: 07/07/2016 01:44 PM] (2) |
| Jul 6, 2016 | 41 | Entry of appearance for Kevin J. Georgek as of counsel for Appellee Supernus Pharmaceuticals, Inc.. Service: 07/06/2016 by email. [348895] [Kevin Georgek] [Entered: 07/06/2016 03:16 PM] (2) |
| May 11, 2016 | 40 | 6 paper copies of the Confidential Opening Brief [37] received from Appellants. [334706] [MJL] [Entered: 05/12/2016 04:18 PM] (0) |
| May 10, 2016 | 39 | Official caption revised pursuant to the court's order filed 5/10/16. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [333740] [AT] [Entered: 05/10/2016 12:13 PM] (0) |
| May 10, 2016 | 38 | ORDER filed. The motion to dismiss [33] is granted. 2016-1621, 2016-1763, and 2016-1764 are dismissed. Each side shall bear its own costs as to those appeals. Appellants' principal brief in 2016-1619 is due no later than May 9, 2016; Appellee's response brief is due no later than July 8, 2016; and Appellants' reply brief is due no later than July 22, 2016. The revised official caption for 2016-1619 is reflected in the order. ISSUED AS A MANDATE (as to 2016-1621, 2016-1763, and 2016-1764 only): May 10, 2016. Service: 05/10/2016 by clerk. [333663] [16-1619, 16-1621, 16-1763, 16-1764] [LMS] [Entered: 05/10/2016 10:20 AM] (3) |
| May 9, 2016 | 37 | CONFIDENTIAL BRIEF FILED for Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida [34]. Number of Pages: 69. Service: 05/09/2016 by US mail. Pursuant to Fed. Cir. R. 28(d)(2)(A) six paper copies should be filed of the confidential version only. [333637] [AT] [Entered: 05/10/2016 09:48 AM] (0) |
| May 9, 2016 | 36 | BRIEF FILED for Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida [35]. Number of Pages: 69. Service: 05/09/2016 by email. Pursuant to Fed. Cir. R. 31(b), filer is directed to file six copies of the confidential version of the brief in paper format. The paper copies should be received by the court on or before 05/16/2016. [333636] [AT] [Entered: 05/10/2016 09:46 AM] (274) |
| May 9, 2016 | 35 | TENDERED from Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida. Title: OPENING BRIEF. Service: 05/09/2016 by email. [333518] [Charles Weiss] [Entered: 05/09/2016 07:43 PM] (274) |
| May 9, 2016 | 34 | TENDERED from Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida. Title: CONFIDENTIAL OPENING BRIEF Service: 05/09/2016 by email, US mail. [333517] [Charles Weiss] [Entered: 05/09/2016 07:37 PM] (0) |
| May 4, 2016 | 33 | MOTION of Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc., Watson Laboratories, Inc. - Florida and Cross-Appellant Supernus Pharmaceuticals, Inc. to terminate appeal through dismissal (as it relates to U.S. Patent No. 8,617,600)., to terminate cross/consolidated appeal. Response/Opposition is due 05/19/2016, to set briefing schedule. Response/Opposition is due 05/19/2016, to modify the official caption. Response/Opposition is due 05/19/2016 [Consent: unopposed]. Service: 05/04/2016 by email. [332155] [Nicholas Giove] [Entered: 05/04/2016 01:27 PM] (8) |
| Apr 21, 2016 | 32 | ORDER filed. The motion [31] is granted. The appellants' opening brief is due May 9, 2016, the cross-appellant's opening brief is due July 8, 2016, the appellants' response and reply brief is due August 17, 2016, and the cross-appellant's reply brief is due August 31, 2016. Service: 04/21/2016 by clerk. [328431] [LMS] [Entered: 04/21/2016 12:27 PM] (2) |
| Apr 13, 2016 | 31 | MOTION of Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida to extend the time to 05/09/2016 to file the appellant/petitioner's principal brief. Response/Opposition is due 04/28/2016, to set briefing schedule. Response/Opposition is due 04/28/2016 [Consent: unopposed]. Service: 04/13/2016 by email. [326245] [Charles Weiss] [Entered: 04/13/2016 05:34 PM] (4) |
| Apr 11, 2016 | 30 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Cross-Appellant Supernus Pharmaceuticals, Inc.. Service: 04/11/2016 by email. [325404] [Nicholas Giove] [Entered: 04/11/2016 03:12 PM] (3) |
| Apr 11, 2016 | 29 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida. Service: 04/11/2016 by email. [325382] [Charles Weiss] [Entered: 04/11/2016 02:42 PM] (3) |
| Apr 6, 2016 | 28 | Amended Docketing Statement for the Cross-Appellant Supernus Pharmaceuticals, Inc.. Service: 04/06/2016 by email. [324527] [Nicholas Giove] [Entered: 04/06/2016 02:34 PM] (4) |
| Apr 4, 2016 | 27 | Transcript Purchase Order Form for the Cross-Appellant Supernus Pharmaceuticals, Inc. indicating that a transcript is already on file. Service: 04/04/2016 by email. [323784] [Nicholas Giove] [Entered: 04/04/2016 04:53 PM] (2) |
| Mar 29, 2016 | 26 | Entry of appearance for Leslie J. Kushner as of counsel for Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida. Service: 03/29/2016 by email. [322428] [Leslie Kushner] [Entered: 03/29/2016 11:46 AM] (2) |
| Mar 24, 2016 | 25 | Official caption revised to reflect the cross appeals 2016-1763 and 2016-1764 which were docketed 3/24/16. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [321483] [AT] [Entered: 03/24/2016 02:57 PM] (0) |
| Mar 24, 2016 | 24 | Note to file: The following cases are associated: LEAD APPEAL 2016-1619 and cross appeals 2016-1763 and 2016-1764. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [321480] [AT] [Entered: 03/24/2016 02:55 PM] (0) |
| Mar 9, 2016 | 23 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:attorney entry of appearance for HOWARD SUH Docket No. [22], ERROR: Mr. Suh's entry of appearance reflects a law firm affiliation [Holland & Knight] that does not match the attorney's ECF filer account or the bar records of the court, which identify counsel's firm as Kirkland & Ellis. CORRECTION: Mr. Suh should promptly update his ECF filer account to reflect his accurate law firm affiliation. Go to www.pacer.gov "manage my appellate filer account". THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [316921] [AT] [Entered: 03/09/2016 08:00 AM] (0) |
| Mar 8, 2016 | 22 | Entry of appearance for Howard S. Suh as of counsel for Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida. Service: 03/08/2016 by email. [316802] [Howard Suh] [Entered: 03/08/2016 03:22 PM] (2) |
| Mar 8, 2016 | 21 | Docketing Statement for the Appellee Supernus Pharmaceuticals, Inc.. Service: 03/08/2016 by email. [316776] [Nicholas Giove] [Entered: 03/08/2016 02:41 PM] (4) |
| Mar 8, 2016 | 20 | Notice of intent to file corresponding briefs on CD-ROM for Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc., Watson Laboratories, Inc. - Florida and Appellee Supernus Pharmaceuticals, Inc.. Service: 03/08/2016 by email. [316771] [Nicholas Giove] [Entered: 03/08/2016 02:38 PM] (4) |
| Mar 7, 2016 | 19 | Docketing Statement for the Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida. Service: 03/07/2016 by email. [316487] [Charles Weiss] [Entered: 03/07/2016 05:18 PM] (3) |
| Mar 7, 2016 | 18 | Entry of appearance for Nicholas P. Chiara as of counsel for Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida. Service: 03/07/2016 by email. [316470] [Nicholas Chiara] [Entered: 03/07/2016 04:43 PM] (2) |
| Mar 7, 2016 | 17 | Entry of appearance for Eric H. Yecies as of counsel for Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida. Service: 03/07/2016 by email. [316459] [Eric Yecies] [Entered: 03/07/2016 04:33 PM] (2) |
| Mar 4, 2016 | 16 | Certificate of Interest for the Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida. Service: 03/04/2016 by email. [316082] [Charles Weiss] [Entered: 03/04/2016 04:49 PM] (2) |
| Mar 4, 2016 | 15 | Entry of appearance for Charles A. Weiss as principal counsel for Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida. Service: 03/04/2016 by email. [316077] [Charles Weiss] [Entered: 03/04/2016 04:45 PM] (2) |
| Mar 3, 2016 | 14 | Transcript Purchase Order Form for the Appellants Actavis Inc., Actavis Pharma, Inc., Anda, Inc., Watson Laboratories, Inc. and Watson Laboratories, Inc. - Florida indicating that a transcript is already on file. Service: 03/03/2016 by email. [315831] [Liza Walsh] [Entered: 03/03/2016 07:34 PM] (3) |
| Mar 3, 2016 | 13 | Certificate of Interest for the Appellee Supernus Pharmaceuticals, Inc.. Service: 03/03/2016 by email. [315779] [Nicholas Giove] [Entered: 03/03/2016 03:38 PM] (2) |
| Mar 3, 2016 | 12 | Amended Entry of appearance for Jonathan A. Herstoff as of counsel for Appellee Supernus Pharmaceuticals, Inc.. Service: 03/03/2016 by email. [315765] [Nicholas Giove] [Entered: 03/03/2016 03:17 PM] (2) |
| Mar 3, 2016 | 11 | Amended Entry of appearance for Nicholas F. Giove as of counsel for Appellee Supernus Pharmaceuticals, Inc.. Service: 03/03/2016 by email. [315763] [Nicholas Giove] [Entered: 03/03/2016 03:15 PM] (2) |
| Mar 3, 2016 | 10 | Amended Entry of appearance for Edgar H. Haug as principal counsel for Appellee Supernus Pharmaceuticals, Inc.. Service: 03/03/2016 by email. [315759] [Nicholas Giove] [Entered: 03/03/2016 03:09 PM] (2) |
| Mar 3, 2016 | 9 | Entry of appearance for William C. Baton as of counsel for Appellee Supernus Pharmaceuticals, Inc.. Service: 03/03/2016 by email. [315751] [Nicholas Giove] [Entered: 03/03/2016 02:55 PM] (2) |
| Mar 3, 2016 | 8 | Entry of appearance for Charles M. Lizza as of counsel for Appellee Supernus Pharmaceuticals, Inc.. Service: 03/03/2016 by email. [315750] [Nicholas Giove] [Entered: 03/03/2016 02:54 PM] (2) |
| Mar 3, 2016 | 7 | Entry of appearance for Andrew Scott Roper as of counsel for Appellee Supernus Pharmaceuticals, Inc.. Service: 03/03/2016 by email. [315747] [Nicholas Giove] [Entered: 03/03/2016 02:52 PM] (2) |
| Mar 3, 2016 | 6 | Entry of appearance for Rachael P. McClure as of counsel for Appellee Supernus Pharmaceuticals, Inc.. Service: 03/03/2016 by email. [315744] [Nicholas Giove] [Entered: 03/03/2016 02:50 PM] (2) |
| Feb 24, 2016 | 5 | Entry of appearance for Jonathan A. Herstoff as of counsel for Appellee Supernus Pharmaceuticals, Inc.. Service: 02/24/2016 by email. [313690] [Nicholas Giove] [Entered: 02/24/2016 03:30 PM] (2) |
| Feb 24, 2016 | 4 | Entry of appearance for Nicholas F. Giove as of counsel for Appellee Supernus Pharmaceuticals, Inc.. Service: 02/24/2016 by email. [313687] [Nicholas Giove] [Entered: 02/24/2016 03:29 PM] (2) |
| Feb 24, 2016 | 3 | Entry of appearance for Edgar H. Haug as principal counsel for Appellee Supernus Pharmaceuticals, Inc.. Service: 02/24/2016 by email. [313680] [Nicholas Giove] [Entered: 02/24/2016 03:26 PM] (2) |
| Feb 24, 2016 | 2 | Note to file: LEAD APPEAL 2016-1619 is consolidated with appeal 2016-1621. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [313513] [AT] [Entered: 02/24/2016 09:37 AM] (0) |
| Feb 24, 2016 | 1 | Appeal docketed. Received: 02/22/2016. [313501]Entry of Appearance due 03/09/2016. Certificate of Interest is due on 03/09/2016. Docketing Statement due 03/09/2016. Appellants' brief is due 04/25/2016. [AT] [Entered: 02/24/2016 09:24 AM] (187) |
